View Article

Abstract

Diuretics are medicines that make the body pass more urine and salt. They work by blocking sodium (salt) reabsorption in different parts of the kidney: • Proximal tubule – SGLT2 inhibitors, carbonic anhydrase inhibitors. • Loop of Henle – loop diuretics. • Distal tubule – thiazide and thiazide-like diuretics. • Collecting tubule – mineralocorticoid receptor antagonists. Because each type works in a different way, they can be combined for better effect. These drugs are used to treat problems like heart failure, kidney diseases, and high blood pressure. • SGLT2 inhibitors lower blood pressure, protect the heart and kidneys, and don’t disturb sodium or potassium levels. • Acetazolamide helps in acute heart failure. • Loop diuretics reduce high blood pressure and extra fluid in the body, but sometimes cause electrolyte imbalance. • Thiazide diuretics mainly lower blood pressure, but can cause low sodium (hyponatremia) and low potassium (hypokalaemia). • Mineralocorticoid receptor antagonists also protect the heart and kidneys and reduce blood pressure, but may cause high potassium (hyperkalaemia).

Keywords

Diuretics, Classification of diuretics, SGLT2 Inhibitors, Carbonic anhydrase inhibitors, Loop diuretics, Thiazide diuretics. Mineralocorticoid receptor antagonist, Types, Mechanism of action

Introduction

This article explains the main types of diuretics (water pills) and how they are used to treat kidney problems and high blood pressure. Diuretics are medicines that help the body get rid of extra water and salt by making you urinate more. Different types of diuretics work in

different ways, so doctors can combine them for better results. These medicines act on different parts of the kidney’s filtering system — the proximal tubule, loop of Henle, distal tubule, and collecting tubule [1].

Reference

  1. Filippatos TD, Tsimihodimos V, Elisaf MS. How SGLT2 inhibitors lower blood pressure. Expert Opin Pharmacother. 2016;17(12):1581–1583. Shows how SGLT2 inhibitors help reduce blood pressure.
  2. Scheen AJ. Lowering blood pressure in people with type 2 diabetes using SGLT2 inhibitors. Diabetes Res Clin Pract. 2016; 121:204–214.
  3. Bjornstad P, et al. How SGLT2 inhibitors affect sodium in the body and heart failure. J Card Fail. 2021;27(12):1447–1455.
  4. Dekkers CCJ, et al. SGLT2 inhibitors and diabetic kidney disease. Curr Diab Rep. 2018;18(5):27.
  5. Kawasoe S, et al. How SGLT2 inhibitors lower blood pressure in obese people with type 2 diabetes. BMC Pharmacol Toxicol. 2017; 18:23.
  6. Fukuoka S, et al. Diuretic effects of SGLT2 inhibitors in diabetes and heart failure. Int J Cardiol. 2015; 201:1–3.
  7. Griffin M, et al. Empagliflozin’s effects on heart and kidneys. Circulation. 2020;142(11):1028–1039.
  8. Szekeres Z, et al. Effects of SGLT2 inhibitors on fat and cholesterol. Metabolites. 2021;11(2).
  9. Ohara K, et al. How dapagliflozin changes body fluid compared to furosemide and tolvaptan. Nephrology (Carlton). 2019;24(9):904–911.
  10. Karg MV, et al. Dapagliflozin reduces sodium in tissues. Cardiovasc Diabetol. 2018; 17:5.
  11. Noble MIM, et al. Damage to the protective layer in arteries may start heart disease. QJM. 2008;101(7):513–518.
  12. Fels J, et al. Tiny mechanical properties of blood vessel lining. Cell Tissue Res. 2014;355(3):727–737.
  13. Oberleithner H, et al. Too much salt harms the artery lining. Pflugers Arch. 2011;462(4):519–528.
  14. Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007; 356:2064–2072.doi:10.1056/NEJMra067110.
  15. Ellison DH. Diuretic Therapy and Resistance in Patients with Heart Failure. N Engl J Med. 2019; 380:539–548.doi:10.1056/NEJMra1806010.
  16. Rangaswami J, McCullough PA, et al. Diuretics in hea. rt failure and chronic kidney disease: a review. Kidney Int. 2018;93(3): 635–647. doi: 10.1016/j.kint.2017.11.023.

Photo
Akash Jadhav
Corresponding author

Mandesh Institute of Pharmaceutical Science and Research Center, Mhaswad -415509

Photo
Varad Dhobale
Co-author

Mandesh Institute of Pharmaceutical Science and Research Center, Mhaswad -415509

Photo
Aishwarya Pise
Co-author

Mandesh Institute of Pharmaceutical Science and Research Center, Mhaswad -415509

Akash Jadhav*, Varad Dhobale, Aishwarya Pise, Diuretics — A Review of the Current Knowledge, Int. J. Sci. R. Tech., 2025, 2 (11), 432-437. https://doi.org/10.5281/zenodo.17627361

More related articles
Enhancing Drug Delivery: Formulation and Evaluatio...
Sudarshan Mirgal, Dr. Bharat Tekade, Dr. Mohan Kale, ...
Nanomedicines Used in The Treatment of the Rheumat...
Aditya Jagatap, Aniket Gavali, Mayuri Kalokhe , Manali Bavadekar,...
Herbal Treatment for Tuberculosis...
Sayyad Kaifali Adam, Tejaswini Gurud, Sarthak Mote , Ajim Shaikh , Sachin Sapkal, Saurabh Walunjkar,...
Evalution Of Phytochemicals, Antioxidant Potential, And Antibacterial Properties...
Nainesh Modi , Kinjal Damor , Riya Kadia, Milan Dabhi, Dweipayan Goswami , ...
Validated Uv Spectrophotometric Quantification of Dutasteride In Pharmaceutical ...
S. Yuvasri, B. Dhatchinamoorthy, G. Dhivagar, N. Dravid vishal, A. Ganesh, N. Gokulakrishan, ...
Related Articles
Formulation and Evaluation of Colon-Targeted Wheat Grass Tablets Using pH-Depend...
Neelima Devi, Kasala Sindhuja, Kavvampalli Shirisha, Kemidi Srikanth, Kokkonda Rajashekar Reddy, Kol...
The Cultural Significance of Medicinal Plants in Literature and Traditional Medi...
Arnab Roy, Dr. Shraddha Verma, Pragya Pandey, Rituparna Acharyya, Meghna Singh, Anuradha Mahapatra, ...
Review on Probiotics as A Health Supplement...
Prapti Chakraborty, Subhajit Patra, Priyanka Ray, ...
Beyond Alkylation – Cyclophosphamide’s Expanding Role in Cancer Therapy and ...
Mohalkar Krushna, Dr. Tarde Vijay, Dahatonde Abhijit, Munfan Sumit, ...
Enhancing Drug Delivery: Formulation and Evaluation of Novel Effervescent Tablet...
Sudarshan Mirgal, Dr. Bharat Tekade, Dr. Mohan Kale, ...